01 March 2017
News and Views
Links and Services
The latest issue of the Alimentary Pharmacology & Therapeutics estimated the risk of malignancies with anti-tumor necrosis factor-α therapy in inflammatory bowel disease.
Anti-tumor necrosis factor-α (TNFα) antibodies are efficacious in inflammatory bowel di
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors